Hallucinations

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

Retrieved on: 
Tuesday, June 8, 2021
Psychoactive drugs, Drugs, Hallucinations, Stimulants, Hallucinogen, Dissociative, Dissociative drugs, Euphoriants, Lysergic acid diethylamide, Psychedelic drug, Phencyclidine, Empathogen–entactogen

Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

Key Points: 
  • Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.
  • Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.
  • A r eport from Data Bridge Market Research projected that the psychedelic drugs market is expected to gain market growth in the forecast period of 2021 to 2028.
  • Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2021 to 2028 and is expected to reach USD 6,433.94 Million by 2028.

First Female-founded Psychedelic Biotech Company Launches

Retrieved on: 
Friday, June 4, 2021
Alternative medicine, Mental health, Health, Consumer, Women, Pharmaceutical, Biotechnology, Hallucinations, Food and Drug Administration, United States Public Health Service, Psychedelic drug, Life sciences, Medicine

Aphrodite Health , a first-of-its-kind biotech company in the rapidly emerging multibillion dollar psychedelic medicine sector, launches today.

Key Points: 
  • Aphrodite Health , a first-of-its-kind biotech company in the rapidly emerging multibillion dollar psychedelic medicine sector, launches today.
  • Founded by women, and focused on addressing womens mental and physical health with psychedelic enhanced treatments.
  • The company has developed a two pronged approach, with a long term drug discovery program to bring an FDA approved drug to market.
  • Aphrodite Health is a US based female-focused psychedelic biotech company introducing psychedelic medicines to address womens mental and physical health challenges overlooked by modern medicine.

Global Psychedelic Drugs Market Research Report 2021: Analysis by Drug, Route of Administration, Distribution Channel, Pipeline Drugs and Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Alternative medicine, Health, Science, Pharmaceutical, Research, Hallucinations, Psychedelic drug, Psychedelic therapy, Branches of biology

The "Global Psychedelic Drugs Market (2021 Edition) - Analysis By Drug, Route of Administration, Distribution Channel, By Region, By Country: Market Insights, Pipeline Drugs and Forecast with Impact of Covid-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Psychedelic Drugs Market (2021 Edition) - Analysis By Drug, Route of Administration, Distribution Channel, By Region, By Country: Market Insights, Pipeline Drugs and Forecast with Impact of Covid-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Global Psychedelic Drugs Market was valued at USD 3.8 billion in the year 2020.
  • The Psychedelic Drugs market is growing rapidly due to the increasing prevalence of depression and other mental disorders worldwide.
  • The report presents the analysis of Psychedelic Drugs Market for the historical period of 2016-2020 and the forecast period of 2021-2026.

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Retrieved on: 
Thursday, June 3, 2021
Hallucinations, Entheogens, Mycotoxins, Psychoactive drugs, Organophosphates, Psilocybin, Psychedelic drug, Mindset, Hallucinogen, Branches of biology

The selection of Mindsets first lead candidate, MSP-1014, is a significant milestone in our clinical journey.

Key Points: 
  • The selection of Mindsets first lead candidate, MSP-1014, is a significant milestone in our clinical journey.
  • Our next generation psychedelic compounds represent the flourishing evolution of therapeutics to effectively address neurological and neuropsychiatric disorders, said James Lanthier, CEO of Mindset.
  • Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

Wesana Announces Participation at Upcoming Events in June 2021

Retrieved on: 
Tuesday, June 1, 2021
Medical specialties, Clinical medicine, Medicine, Neurotrauma, Neuropharmacology, Hallucinations, Psychopharmacology, Daniel Carcillo, Traumatic brain injury, Psychedelic drug, Kcsa

In addition to the Wesana corporate presentation, Mr. Carcillo will participate in the Disruptive Psychopharmacology An Introduction to Psychedelics and the Coming Revolution in Psychiatry panel at 9:00 a.m.

Key Points: 
  • In addition to the Wesana corporate presentation, Mr. Carcillo will participate in the Disruptive Psychopharmacology An Introduction to Psychedelics and the Coming Revolution in Psychiatry panel at 9:00 a.m.
  • Momentums The Second Annual Psychedelic Opportunity Summit to be held virtually on June 22-23, 2021.
  • For more information about the conferences, or to schedule a one-on-one meeting with Wesana management, please contact KCSA Strategic Communications at [email protected] .
  • Wesana is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI).

Mindset Announces Participation at Upcoming Events in June 2021

Retrieved on: 
Tuesday, June 1, 2021
Health sciences, Branches of biology, Life sciences, Hallucinations, Medication, Pharmaceutical industry, Psychedelic drug, Psychiatry, Pharma

H.C. Wainwright's Psychedelics in Psychiatry and Beyond Conference to be held virtually on Thursday, June 17, 2021.

Key Points: 
  • H.C. Wainwright's Psychedelics in Psychiatry and Beyond Conference to be held virtually on Thursday, June 17, 2021.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.
  • Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • For further information on Mindset, please visit our website at www.mindsetpharma.com .

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations

Retrieved on: 
Thursday, May 27, 2021
Psychoactive drugs, Drugs, Entheogens, Branches of biology, NMDA receptor antagonists, Nicotinic antagonists, Hallucinations, Sedatives, Psychedelic drug, Ketamine, Mescaline, Ibogaine

(MediSynergics), a drug discovery company, to develop MediSynergics patented ketamine derivatives for pain and other CNS disorders and to investigate drug discovery and development of next-generation psychedelic derivatives, such as psilocybin, N,N-Dimethyltryptamine (DMT), 3,4-Methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD), mescaline, and ibogaine.

Key Points: 
  • (MediSynergics), a drug discovery company, to develop MediSynergics patented ketamine derivatives for pain and other CNS disorders and to investigate drug discovery and development of next-generation psychedelic derivatives, such as psilocybin, N,N-Dimethyltryptamine (DMT), 3,4-Methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD), mescaline, and ibogaine.
  • PharmaTher and MediSynergics will initially collaborate to advance the research of MediSynergics patented ketamine derivatives as an alternative to opioid medications for pain disorders using predictive preclinical animal models.
  • Efficacy of the patented ketamine derivatives were demonstrated to be comparable or better than ketamine when tested in a murine capsaicin inflammatory pain model.
  • Fabio Chianelli, Chief Executive Officer of PharmaTher, said, We are excited to work with MediSynergics in the discovery and development of novel psychedelic derivatives and formulations for pain and CNS disorders.

Psychedelic Drug Market Has Become a Billion Dollar Industry As Acceptable Treatments Expand

Retrieved on: 
Tuesday, May 25, 2021
Hallucinations, Psychedelic drug, Branches of biology, Medicine, Clinical medicine, Psychedelic therapy

Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth.

Key Points: 
  • Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth.
  • Currently, different research studies are taking place that are expected to provide a competitive advantage for new and innovative therapeutic manufacturers with competitive psychedelic drugs and methods to develop, define psychedelic drugs, and various other opportunities in the U.S. psychedelic market.
  • It said: "The global psychedelic drugs market has increased significantly during the years 2018-2020 and projections are made that the market would rise in the next four years i.e.
  • Yet the market faces some challenges such as uncertainty around getting the FDA approval, early stage in lifecycle of the psychedelics industry, stigma associated with psychedelic drugs use, etc.

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Retrieved on: 
Thursday, May 20, 2021
Biotechnology, Mental health, Alternative medicine, Health, Pharmaceutical, Entheogens, Hallucinations, Psychoactive fungi, Psychoactive drugs, Psychedelic drug, Health sciences, Nutraceutical, Hallucinogen, Articles

There are numerous risks and uncertainties that could cause actual results and Cybin\xe2\x80\x99s plans and objectives to differ materially from those expressed in the forward-looking information.

Key Points: 
  • There are numerous risks and uncertainties that could cause actual results and Cybin\xe2\x80\x99s plans and objectives to differ materially from those expressed in the forward-looking information.
  • The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products.
  • There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition.
  • Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

Retrieved on: 
Monday, May 17, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Hallucinations, Ketamine, Sedatives, Psychedelic drug

The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.

Key Points: 
  • The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.
  • The IND paves the way for us to expeditiously evaluate ketamine and other psychedelics via the FDA regulatory pathway in various mental illness, neurological and pain disorders.
  • There is currently no cure for Parkinson\xe2\x80\x99s disease, although some drug combinations are used to treat the disease symptoms.
  • The possible therapeutic effect of low-dose ketamine on LID was noted in a retrospective analysis of PD patients who received ketamine for pain relief.